Skip to Main content Skip to Navigation
Journal articles

[Angiotensin-2 type 1 receptors (AT1R) and cancers].

Thibault Dolley-Hitze 1, 2 Grégory Verhoest 2, 3 Florence Jouan 4 Patrick Le Pogamp 1 Yannick Arlot-Bonnemains 4 Emmanuel Oger 5 Marc-Antoine Belaud-Rotureau 6 Nathalie Rioux-Leclercq 7 Cécile Vigneau 1, 2
4 Cancer du rein : bases moléculaires de la tumorogenèse
IGDR - Institut de Génétique et Développement de Rennes
6 Cancer du rein : bases moléculaires de la tumorogenèse
Service de Cytogénétique et de Biologie Cellulaire, IGDR - Institut de Génétique et Développement de Rennes
7 Cancer du rein : bases moléculaires de la tumorogenèse
Service d'anatomie et cytologie pathologiques [Rennes], IGDR - Institut de Génétique et Développement de Rennes
Abstract : Recently, several meta-analysis suggested an increased risk of cancers linked to the use of antagonists of angiotensin-2 receptors or inhibitors of angiotensinogen converting enzyme. The results of epidemiological studies are conflicting. Meta-analysis as well as retrospective studies are not reliable and biased, since they have never been designed to explore any pro- or antitumoral effect. We lack of prospective studies that could take off the doubt on these drugs. Nevertheless, all experimental researches pointed out potent antitumoral properties. Indeed, direct antiproliferative and neo-angiogenic inhibition have been described on tumor cell cultures as well as on animal models. Moreover, we are convinced that the use of antagonists of angiotensin-2 receptors and inhibitors of angiotensinogen converting enzyme may be then of clinical use in the near future in association with classical antitumor drugs. In this review, we proposed to explore these data by a thorough analysis of recent literature associating epidemiological and experimental studies.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00814037
Contributor : Véronique Touya <>
Submitted on : Tuesday, April 16, 2013 - 2:35:09 PM
Last modification on : Thursday, June 18, 2020 - 9:29:11 AM

Identifiers

Citation

Thibault Dolley-Hitze, Grégory Verhoest, Florence Jouan, Patrick Le Pogamp, Yannick Arlot-Bonnemains, et al.. [Angiotensin-2 type 1 receptors (AT1R) and cancers].. Néphrologie et Thérapeutique, Elsevier Masson, 2013, 9 (2), pp.85-91. ⟨10.1016/j.nephro.2012.09.006⟩. ⟨inserm-00814037⟩

Share

Metrics

Record views

619